Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort

Jorja Braden; Alison J. Potter; Robert V. Rawson; Nurudeen A. Adegoke; Serigne Lo; Jordan W. Conway; Alexander M. Menzies; Matteo S. Carlino; George Au‐Yeung; Robyn P.M. Saw; Andrew J. Spillane; Kerwin F. Shannon; Thomas E. Pennington; Sydney Ch'ng; David Gyorki; Julie R. Howle; James S. Wilmott; Richard A Scolyer; Georgina V. Long; Inês Pires da Silva

doi:10.1016/j.modpat.2025.100776

Related publications

Article2022

798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis

Jorja Braden, Alison J. Potter, Elizabeth C. Paver, Robert V. Rawson, Alexander M. Menzies, M.S. Carlino, George Au‐Yeung, Robyn P.M. Saw, Andrew J. Spillane, Kerwin F. Shannon, Thomas E. Pennington, Sydney Ch’ng, D. Gyorki, Julie R. Howle, Dariush Daneshvar, James S. Wilmott, Serigne Lo, I. Pires da Silva, Richard A Scolyer, Georgina V. Long

Article2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen,

Article2015

Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Robyn P.M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna P. Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A Scolyer, Helen Rizos, John F. Thompson, Kerwin F. Shannon, Andrew J. Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long

Article2023

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Irene L. M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W.J.M. Wouters, Andrew J. Spillane, W. Martin C. Klop, Annegien Broeks, Linda J.W. Bosch, Marta López‐Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke I. Plasmeijer, Yannick S. Elshot, Richard A Scolyer, Bart A. van de Wiel, Daniel S. Peeper,

Article2017

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma

Alexander M. Menzies, Maria Gonzalez, Alex Guminski, Omgo E. Nieweg, Kerwin F. Shannon, John F. Thompson, Richard Kefford, Sydney Ch’ng, Jonathan R. Stretch, Andrew J. Spillane, J. Lee, H. Lee, Rony Kapoor, Louise Emmett, Helen Rizos, Robyn P.M. Saw, Richard A Scolyer, Georgina V. Long